pharmaphorum| News & views on pharma and biotech’s evolving future

News

Are Makary's priority review vouchers about to be canned?

Reports are emerging that the national priority voucher scheme launched by former FDA chief Marty Makary may be heading for the scrap heap.

News

NHS use of Incyte's anal cancer drug Zynyz backed by NICE

Hundreds of patients in England and Wales with anal cancer could soon be eligible for treatment with Incyte's cancer immunotherapy Zynyz.

Patients

Five diseases that changed rare disease R&D

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

News

Blackstone buys into Pfizer's GLP-1 drug development

Blackstone Life Sciences will provide up to $1.5bn in funding to Pfizer for the development of its once-monthly GLP-1 agonist berobenatide.

Featured Content

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

Patients

Rare diseases are not a niche, but Europe’s opportunity to c...

Rare diseases are individually uncommon, but collectively affect up to 36 million people in the European Union.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

Sponsored

Securing your ROI: Turning post-acquisition integration into...

Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.

Patients

pharmaphorum podcast Episode 285, Donna Cryer, CryerHealth, LLC

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.

Sales & Marketing

Sponsored

Are Insights leaders seeing real commercial value from AI ad...

Day One Strategy’s second annual AI in Pharma State of Play report addresses the challenges Pharma Insights teams are facing as AI adoption continues.

Newsletters and Deep Dive
digital magazine

Latest News

News

Are Makary's priority review vouchers about to be canned?

Reports are emerging that the national priority voucher scheme launched by former FDA chief Marty Makary may be heading for the scrap heap.

News

NHS use of Incyte's anal cancer drug Zynyz backed by NICE

Hundreds of patients in England and Wales with anal cancer could soon be eligible for treatment with Incyte's cancer immunotherapy Zynyz.

News

Blackstone buys into Pfizer's GLP-1 drug development

Blackstone Life Sciences will provide up to $1.5bn in funding to Pfizer for the development of its once-monthly GLP-1 agonist berobenatide.

News

Lilly beats Novo to China with an oral GLP-1 for obesity

Lilly's orforglipron has been approved in China, becoming the first oral GLP-1 agonist to enter the Chinese weight management market.

Views & Analysis

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

R&D

From phase 1 to phase 3: Scaling radiopharmaceutical trials

Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.

Patients

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

R&D

Gravity is an experimental variable pharma has rarely been a...

Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.

Deep Dive

Patients

Deep Dive Rare Disease 2026

Patients

Five diseases that changed rare disease R&D

Patients

Rare diseases are not a niche, but Europe’s opportunity to c...

Rare diseases are individually uncommon, but collectively affect up to 36 million people in the European Union.

Patients

The UK Rare Diseases Framework: Ensuring healthy equity for ...

White Papers & Webinar

Sales & Marketing

Sponsored

Securing your ROI: Turning post-acquisition integration into...

Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.

Sales & Marketing

Sponsored

Are Insights leaders seeing real commercial value from AI ad...

Day One Strategy’s second annual AI in Pharma State of Play report addresses the challenges Pharma Insights teams are facing as AI adoption continues.

Digital

IQVIA Technologies White Paper Cover Image

Sponsored

From Automation to Decision Intelligence: The Next Operating...

In this free white paper, IQVIA experts and thought leaders explore the real challenges and bottlenecks in pharmacovigilance today.

Digital

The State of AI in Clinical Trials White Paper

Sponsored

From Pilot to Practice: Insights into AI Adoption, Impact, a...

Read Medidata’s 2nd annual survey, 'The State of AI in Clinical Trials. From Pilot to Practice: Insights into AI Adoption, Impact, and Expectations'.

Podcasts & Video

Patients

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.

Oncology

On the benefits of earlier oncological intervention, with Jo...

As ESMO 2026 came to a close, pharmaphorum web editor Nicole Raleigh spoke with Johnson & Johnson Innovative Medicine’s Carolyn Sousa and Henar Hevia

Digital

pharmaphorum podcast Episode 284, Mati Gill, AION Labs

AI, start-ups, and the future of human health: AION Labs’ Ma...

In a new episode of the pharmaphorum podcast, Nicole Raleigh invites Mati Gill, CEO of AION Labs, back as guest.

Partner Content

Media Partner

The PM Awards aren’t just for agencies. They’re for the peop...

For decades, the PM Awards have been a fixture in the pharma and healthcare communications calendar

Partner Content

PMi Awards 2026: innovation, connection and a changing indus...

One of the things I enjoyed most about this year’s PM Society PMi Awards was the sheer breadth of the community in the room.

Partner Content

LEAP HR: Life Sciences Europe

Europe’s Only Industry-Specific Meeting Advancing HR Excellence in Life Sciences

Partner Content

Rational Based Drug Design Summit Europe

Driving Safer, Faster & More Efficient Discovery Across Europe

Event

Media Partner

Evolution Summit 2027 to Convene Senior Clinical Development...

Westlake Village, CA: Marcus Evans today announced the Evolution Summit 2027, an invitation-only gathering of senior clinical trial executives

Featured Content

Editor's Picks

Latest News

Views & Analysis

Deep Dive

White Papers & Webinar

Podcasts & Video

Partner Content